• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

囊性纤维化中营养状况的变化:超重和肥胖的出现。

The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity.

机构信息

Division of Pulmonary, Allergy and Critical Care Medicine, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

Gregory Fleming James Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL 35294, USA.

出版信息

Nutrients. 2022 Mar 13;14(6):1216. doi: 10.3390/nu14061216.

DOI:10.3390/nu14061216
PMID:35334873
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8953232/
Abstract

Cystic fibrosis has historically been characterized by malnutrition, and nutrition strategies have placed emphasis on weight gain due to its association with better pulmonary outcomes. As treatment for this disease has significantly improved, longevity has increased and overweight and obesity have emerged issues in this population. The effect of excess weight and adiposity on CF clinical outcomes is unknown but may produce similar health consequences and obesity-related diseases as those observed in the general population. This review examines the prevalence of overweight and obesity in CF, the medical and psychological impact, as well as the existing evidence for treatment in the general population and how this may be applied to people with CF. Clinicians should partner with individuals with CF and their families to provide a personalized, interdisciplinary approach that includes dietary modification, physical activity, and behavioral intervention. Additional research is needed to identify the optimal strategies for preventing and addressing overweight and obesity in CF.

摘要

囊性纤维化历来以营养不良为特征,由于其与更好的肺部预后相关,营养策略一直侧重于体重增加。随着这种疾病的治疗有了显著改善,患者的寿命延长了,超重和肥胖已成为该人群的问题。超重和肥胖对 CF 临床结果的影响尚不清楚,但可能会产生与普通人群中观察到的类似的健康后果和与肥胖相关的疾病。本文综述了 CF 患者中超重和肥胖的流行情况、对医疗和心理的影响,以及在普通人群中治疗的现有证据,以及如何将这些证据应用于 CF 患者。临床医生应与 CF 患者及其家属合作,提供个性化的、跨学科的方法,包括饮食调整、身体活动和行为干预。需要进一步研究以确定预防和解决 CF 中超重和肥胖的最佳策略。

相似文献

1
The Changing Landscape of Nutrition in Cystic Fibrosis: The Emergence of Overweight and Obesity.囊性纤维化中营养状况的变化:超重和肥胖的出现。
Nutrients. 2022 Mar 13;14(6):1216. doi: 10.3390/nu14061216.
2
Overweight and cystic fibrosis: An unexpected challenge.超重与囊性纤维化:一项意想不到的挑战。
Pediatr Pulmonol. 2022 Feb;57 Suppl 1:S40-S49. doi: 10.1002/ppul.25748. Epub 2021 Nov 12.
3
Prevalence of malnutrition and obesity among cystic fibrosis patients.囊性纤维化患者中营养不良和肥胖的患病率。
Pediatr Int. 2014 Feb;56(1):89-94. doi: 10.1111/ped.12214.
4
Nutritional status in the era of highly effective CFTR modulators.高效 CFTR 调节剂时代的营养状况。
Pediatr Pulmonol. 2024 Sep;59 Suppl 1:S6-S16. doi: 10.1002/ppul.26806.
5
Prevalence and factors associated with overweight and obesity in adults with cystic fibrosis: A single-center analysis.囊性纤维化成人超重和肥胖的患病率及相关因素:一项单中心分析。
J Cyst Fibros. 2020 Jan;19(1):139-145. doi: 10.1016/j.jcf.2019.10.004. Epub 2019 Nov 11.
6
Overweight and obesity in patients with cystic fibrosis: a center-based analysis.囊性纤维化患者的超重与肥胖:一项基于中心的分析。
Pediatr Pulmonol. 2015 Jan;50(1):35-41. doi: 10.1002/ppul.23033. Epub 2014 Apr 23.
7
Body composition and lung function in cystic fibrosis and their association with adiposity and normal-weight obesity.囊性纤维化患者的身体组成与肺功能及其与肥胖和正常体重肥胖的关联
Nutrition. 2016 Apr;32(4):447-52. doi: 10.1016/j.nut.2015.10.012. Epub 2015 Oct 30.
8
Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry.囊性纤维化中的肥胖症:来自美国囊性纤维化基金会患者登记处的患病率、趋势及相关因素数据
J Cyst Fibros. 2022 Sep;21(5):777-783. doi: 10.1016/j.jcf.2022.03.010. Epub 2022 Apr 5.
9
A paradigm shift in cystic fibrosis nutritional care: Clinicians' views on the management of patients with overweight and obesity.囊性纤维化营养护理的范式转变:临床医生对超重和肥胖患者管理的看法。
J Cyst Fibros. 2023 Sep;22(5):836-842. doi: 10.1016/j.jcf.2023.03.011. Epub 2023 Mar 23.
10
Association of Body Mass Index With Clinical Outcomes in Patients With Cystic Fibrosis: A Systematic Review and Meta-analysis.体质指数与囊性纤维化患者临床结局的相关性:系统评价和荟萃分析。
JAMA Netw Open. 2022 Mar 1;5(3):e220740. doi: 10.1001/jamanetworkopen.2022.0740.

引用本文的文献

1
Glucagon-Like Peptide 1 Agonist Use in an Adult With Cystic Fibrosis-Related Diabetes and Metabolic Syndrome.胰高血糖素样肽1激动剂在一名患有囊性纤维化相关糖尿病和代谢综合征的成人中的应用。
AACE Endocrinol Diabetes. 2025 Apr 11;12(2):67-70. doi: 10.1016/j.aed.2025.03.011. eCollection 2025 Jul-Aug.
2
Nutritional and Morphofunctional Assessment in a Cohort of Adults Living with Cystic Fibrosis with or Without Pancreatic Exocrine and/or Endocrine Involvement.对一组患有或未患有胰腺外分泌和/或内分泌功能障碍的成年囊性纤维化患者进行营养及形态功能评估。
Nutrients. 2025 Jun 20;17(13):2057. doi: 10.3390/nu17132057.
3
Evolving nutrition therapy in cystic fibrosis: Adapting to the CFTR modulator era.囊性纤维化中不断发展的营养治疗:适应CFTR调节剂时代。
Nutr Clin Pract. 2025 Aug;40(4):816-828. doi: 10.1002/ncp.11332. Epub 2025 Jun 18.
4
Sex disparities in cystic fibrosis in the era of highly effective modulator treatment.高效调节剂治疗时代囊性纤维化中的性别差异。
BMC Pulm Med. 2025 May 2;25(1):212. doi: 10.1186/s12890-025-03621-0.
5
The Aging Patient with Cystic Fibrosis.患有囊性纤维化的老年患者
Drugs Aging. 2025 Apr 24. doi: 10.1007/s40266-025-01207-3.
6
A systematic review of the impact of Elexacaftor/Tezacaftor/Ivacaftor on body composition in people with cystic fibrosis.依列卡福妥/替扎卡福妥/依伐卡托对囊性纤维化患者身体成分影响的系统评价
Eur J Clin Nutr. 2025 Mar 22. doi: 10.1038/s41430-025-01589-y.
7
Pilot and feasibility study of dietary composition with elexacaftor-tezacaftor-ivacaftor concentrations in people with cystic fibrosis.囊性纤维化患者饮食成分与依列卡福-替扎卡福-依伐卡福浓度的初步和可行性研究
Pharmacotherapy. 2024 Dec;44(12):920-926. doi: 10.1002/phar.4630. Epub 2024 Dec 23.
8
Heightened mitochondrial respiration in CF cells is normalised by triple CFTR modulator therapy through mechanisms involving calcium.通过涉及钙的机制,三联CFTR调节剂疗法可使囊性纤维化(CF)细胞中增强的线粒体呼吸恢复正常。
Heliyon. 2024 Oct 11;10(20):e39244. doi: 10.1016/j.heliyon.2024.e39244. eCollection 2024 Oct 30.
9
Is Obesity a Problem in New Cystic Fibrosis Treatments?肥胖症是否成为新的囊性纤维化治疗方法的问题?
Nutrients. 2024 Sep 14;16(18):3103. doi: 10.3390/nu16183103.
10
Hope in Every Breath: Navigating the Therapeutic Landscape of Cystic Fibrosis.每一次呼吸中的希望:探索囊性纤维化的治疗前景
Cureus. 2023 Aug 16;15(8):e43603. doi: 10.7759/cureus.43603. eCollection 2023 Aug.

本文引用的文献

1
Nutritional status and lung function in children with pancreatic-sufficient cystic fibrosis.胰腺功能正常的囊性纤维化患儿的营养状况与肺功能
J Cyst Fibros. 2022 Sep;21(5):769-776. doi: 10.1016/j.jcf.2021.12.014. Epub 2021 Dec 28.
2
Patient and family experience of telehealth care delivery as part of the CF chronic care model early in the COVID-19 pandemic.患者及其家属在 COVID-19 大流行早期体验作为 CF 慢性病管理模式一部分的远程医疗护理。
J Cyst Fibros. 2021 Dec;20 Suppl 3:41-46. doi: 10.1016/j.jcf.2021.09.005.
3
Eating disorders and body image in cystic fibrosis.囊性纤维化患者的饮食失调与身体意象
J Clin Transl Endocrinol. 2021 Nov 26;26:100280. doi: 10.1016/j.jcte.2021.100280. eCollection 2021 Dec.
4
Perception, experience and relationship with food and eating in adults with cystic fibrosis.囊性纤维化成人的食物感知、体验和与食物的关系。
J Hum Nutr Diet. 2022 Oct;35(5):757-764. doi: 10.1111/jhn.12967. Epub 2021 Dec 16.
5
Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis.依伐卡托与泰比卡托联合艾乐卡福特治疗对成年囊性纤维化患者体重和代谢参数的影响。
J Cyst Fibros. 2022 Mar;21(2):265-271. doi: 10.1016/j.jcf.2021.11.012. Epub 2021 Dec 1.
6
CFTR modulators increase risk of acute pancreatitis in pancreatic insufficient patients with cystic fibrosis.CFTR 调节剂增加胰腺功能不全的囊性纤维化患者发生急性胰腺炎的风险。
J Cyst Fibros. 2022 Jul;21(4):600-602. doi: 10.1016/j.jcf.2021.09.010. Epub 2021 Oct 31.
7
Overweight and obesity in adults with cystic fibrosis: An Italian multicenter cohort study.成人囊性纤维化患者超重和肥胖:一项意大利多中心队列研究。
J Cyst Fibros. 2022 Jan;21(1):111-114. doi: 10.1016/j.jcf.2021.05.002. Epub 2021 May 27.
8
Patient and family perceptions of telehealth as part of the cystic fibrosis care model during COVID-19.在新冠疫情期间,患者及家属对远程医疗作为囊性纤维化护理模式一部分的看法。
J Cyst Fibros. 2021 May;20(3):e23-e28. doi: 10.1016/j.jcf.2021.03.009. Epub 2021 Mar 26.
9
Body composition and weight changes after ivacaftor treatment in adults with cystic fibrosis carrying the G551 D cystic fibrosis transmembrane conductance regulator mutation: A double-blind, placebo-controlled, randomized, crossover study with open-label extension.携带 G551D 囊性纤维化跨膜电导调节子突变的成年囊性纤维化患者接受 ivacaftor 治疗后的身体成分和体重变化:一项双盲、安慰剂对照、随机、交叉研究加开放标签扩展。
Nutrition. 2021 May;85:111124. doi: 10.1016/j.nut.2020.111124. Epub 2021 Feb 8.
10
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.G551D 突变型 CFTR 患者使用伊伐卡托的长期临床疗效。
J Cyst Fibros. 2021 Mar;20(2):213-219. doi: 10.1016/j.jcf.2020.11.008. Epub 2020 Nov 25.